Waldron Private Wealth LLC Makes New Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Waldron Private Wealth LLC bought a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,182 shares of the medical device company’s stock, valued at approximately $50,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock valued at $207,708,000 after purchasing an additional 18,571 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Tandem Diabetes Care by 79.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,788 shares of the medical device company’s stock worth $171,000 after buying an additional 2,562 shares in the last quarter. Park Avenue Securities LLC raised its position in shares of Tandem Diabetes Care by 20.3% in the first quarter. Park Avenue Securities LLC now owns 8,650 shares of the medical device company’s stock valued at $306,000 after buying an additional 1,459 shares during the last quarter. MCF Advisors LLC lifted its stake in shares of Tandem Diabetes Care by 79.3% in the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after buying an additional 445 shares in the last quarter. Finally, LVW Advisors LLC purchased a new position in shares of Tandem Diabetes Care in the first quarter worth about $242,000.

Analysts Set New Price Targets

TNDM has been the subject of several research reports. Piper Sandler reaffirmed an “overweight” rating and set a $55.00 price objective (up previously from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Wells Fargo & Company upped their price target on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Canaccord Genuity Group assumed coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They set a “buy” rating and a $57.00 price objective on the stock. The Goldman Sachs Group started coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They issued a “neutral” rating and a $46.00 target price for the company. Finally, Morgan Stanley reissued an “equal weight” rating and set a $45.00 price target on shares of Tandem Diabetes Care in a research report on Monday, September 23rd. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and an average price target of $55.13.

Tandem Diabetes Care Trading Down 4.1 %

Shares of NASDAQ TNDM opened at $32.15 on Thursday. The company has a current ratio of 3.05, a quick ratio of 2.38 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $2.08 billion, a PE ratio of -14.82 and a beta of 1.33. Tandem Diabetes Care, Inc. has a twelve month low of $13.82 and a twelve month high of $53.69. The stock has a fifty day simple moving average of $41.52 and a 200-day simple moving average of $41.90.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. The company had revenue of $221.90 million during the quarter, compared to the consensus estimate of $205.63 million. Tandem Diabetes Care had a negative return on equity of 41.54% and a negative net margin of 17.15%. Tandem Diabetes Care’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.30) EPS. On average, equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.76 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.